Article Text

PDF

Does endothelin-1 reduce superior mesenteric artery blood flow velocity in preterm neonates?
  1. Fiona J Weira,
  2. Arne Ohlssona,d,
  3. Katherine Fongb,
  4. Kofi Amankwahc,
  5. Flavio Coceanie
  1. aDepartment of Newborn and Developmental Paediatrics, Women’s College Hospital, Toronto, Ontario, Canada, bDepartment of Medical Imaging, cDepartment of Obstetrics and Gynaecology, dMaternal, Infant and Reproductive Health Research Unit, eHospital for Sick Children, Integrative Biology Program
  1. Dr Arne Ohlsson Department of Paediatrics Mount Sinai Hospital 600 University Street, Toronto, Ontario, M5S 1B2. Email: aohlsson{at}mtsinai.on.ca

Abstract

AIM To compare plasma endothelin-1 (ET-1) concentrations in preterm neonates from pre-eclamptic and normal mothers; and to evaluate whether ET-1 has a role in altered arterial blood flow velocity.

METHODS Umbilical arterial blood and neonatal arterial blood were sampled on days 1 and 3 for gas analysis and measurement of plasma ET-1. Doppler ultrasonography of the middle cerebral, renal, and superior mesenteric arteries (SMA) was performed.

RESULTS Neonates in the pre-eclampsia (n=18) and control (n=18) groups had mean (SD) gestational ages of 31.1 (2.5) weeks and 30.4 (2.1) weeks; their birthweights were 1432 (SD 676) g and 1692 (SD 500) g, respectively. In the pre-eclampsia group mean umbilical arterial PO2 was lower—1.88 (0.75) kPa compared with 3.27 (1.41) kPa (p < 0.01)—and mean plasma ET-1 concentration was higher in the umbilical artery—40.6 (SD 15.0) compared with 30.5 (SD 13.8) pg/ml (p=0.04) and day 1 blood—54.9 (35.0) pg/ml compared with 33.6 (14.6) pg/ml (p=0.03). Middle cerebral artery peak systolic velocity was higher and SMA time averaged, peak systolic, and mean peak velocities were lower in the pre-eclampsia group. SMA time averaged velocity was inversely related to plasma ET-1 concentration.

CONCLUSION The association between increased production of ET-1 and reduction in SMA time averaged velocity suggests a possible mechanism for hypoperfusion of the intestinal wall in neonates.

  • eclampsia
  • hypoxia
  • vasoconstriction
  • endothelin-1

Statistics from Altmetric.com

Endothelins are a family of peptides synthesised by many tissues. Among them, endothelin-1 (ET-1) is produced in the vessel wall by both endothelial and smooth muscle cells.1 2 ET-1 is a powerful vasoconstrictor, which acts through specific ETAreceptors on smooth muscle cells. On endothelial cells, ETBreceptor stimulation causes the release of nitric oxide. Stimuli for ET-1 include hypoxia and shear stress.1 3 Hypoxia directly stimulates ET-1 secretion by rat mesenteric artery in vitro4 and infusion of ET-1 causes an increase in peripheral vascular resistance predominantly in the gastrointestinal, renal, and skeletal muscle vascular beds.5 ET-1 may therefore have a pathophysiological role in hypoxia–ischaemia, specifically as a precipitating factor in the development of necrotising enterocolitis.6

We have shown that fetal blood vessels have a functioning ET-1 system in lambs, which, depending on the site, may be activated by an increase (ductus arteriosus)7 or decrease (pulmonary vasculature)8 in oxygen tension. In humans umbilical cord blood ET-1 concentration is raised at birth in asphyxia,9pre-eclampsia, and intrauterine growth retardation.10-12Increased circulating concentrations of ET-1 in neonates with persistent pulmonary hypertension13 14 or respiratory distress syndrome,15 and increased urinary concentrations of ET-1 in neonates with post-hypoxic renal failure16 have been described.

In pre-eclampsia reduced placental transport of oxygen and nutrients results in fetal hypoxia and often growth retardation. Clinical and animal studies suggest that an hypoxic fetus attempts to preserve cerebral perfusion at the expense of visceral perfusion.17 18 Studies of fetuses and neonates with growth retardation or abnormal umbilical arterial blood flow velocity have shown an association between fetal hypoxia and perinatal asphyxia, hyperviscosity, necrotising enterocolitis, renal failure and haemorrhage.19 20 Nevertheless, studies have not simultaneously measured ET-1 and organ blood flow velocities.

We hypothesised that in pre-eclampsia fetal hypoxaemia upregulates the ET-1 system in blood vessels. This in turn would lead to vasoconstriction and impaired regional blood flow in the neonate. This study aimed to determine the effect of fetal hypoxaemia caused by pre-eclampsia on ET-1 production and organ blood flow velocity in preterm infants.

Methods

Mothers at risk of preterm delivery between 26 and 34 weeks of gestation, admitted to Women’s College Hospital, were eligible for study. The pre-eclampsia group comprised mothers with pregnancy induced hypertension plus proteinuria, and the control group comprised mothers with normal blood pressure, in spontaneous preterm labour. Mothers were excluded if they developed chorioamnionitis, antepartum haemorrhage, or if a congenital anomaly was recognised in the infant before or after birth. Written, informed consent was obtained from mothers before delivery for participation in the study.

Venous blood from the mother was drawn before delivery. Umbilical arterial samples were obtained after double clamping the cord at birth. Arterial blood was obtained through indwelling arterial, central, or peripheral catheters, or by puncture of a peripheral artery. Blood samples were drawn at the same time as sampling of arterial blood was indicated for other purposes and when the neonates were clinically stable. Samples were obtained from the neonates at 1 to 12 hours (day 1) and 48 to 72 hours (day 3) of age. The whole blood was added to chilled, EDTA coated Microtainer tubes that were centrifuged at 4000 rpm for 5 minutes. The plasma was collected and stored at −80oC.

ET-1 was extracted from plasma on SepPak C18 cartridges. Radioimmunoassay was performed, using an antibody to human ET-1 from Peninsula Laboratories. The sensitivity of the assay is about 2 pg per sample. The procedure and its validation have been reported before.2

Doppler ultrasonography of the right middle cerebral (MCA), right renal (RA), and superior mesenteric (SMA) artery was performed within 1 hour of the blood sampling for ET-1 assay on days 1 and 3. Neonates were examined while asleep or in an awake–quiet state. In neonates receiving enteral feeds, studies were performed 90 to 120 minutes after a feed. Examinations were performed using an ATL Ultramark 9, with a 5 MHz phased array sector transducer. We have already reported the technique for Doppler sonography of the MCA,21 RA, and SMA.22 All arteries were evidenced by colour Doppler imaging with flow towards the transducer mapped in red and away from the transducer in blue. The MCA was visualised between the temporal and frontal bones in an axial plane. To visualise the right renal artery, the neonate lay in a decubitus position and a coronal image of the kidney was obtained. The Doppler sample volume was placed in the proximal RA. The epigastrium was then examined. Colour Doppler imaging was used to localise the origin of the SMA from the aorta in a longitudinal plane. The Doppler sample volume was placed in the proximal SMA. A Doppler sample volume size of 1.5 mm was used and a wall filter of 50 Hz for the RA and 100 Hz for the MCA and the SMA. When indicated, angle correction was used for accurate velocity display. The optimal spectral trace from each artery containing a minimum of five consecutive waveforms was recorded on to videotape for later analysis of heart rate, peak systolic velocity (PS), end diastolic velocity (ED) and mean velocity (MV). The time averaged velocity (TAV) is calculated from the waveforms at the time of study. The examination was stopped if the neonate showed discomfort. Any left to right shunt across the ductus arteriosus was identified with colour Doppler, according to the method of Swensson et al.23 The total examination time, including ultrasound scanning of all three vessels, was limited to 30 minutes.

Parametric and non-parametric tests were used for statistical analyses. One way analysis of variance (ANOVA) was used to compare the groups for plasma ET-1 concentration, while ANOVA for repeated measures was used to compare the measurements of MCA, SMA, and RA blood flow velocity between groups. Where a significant difference in TAV between groups was found, linear regression was used to establish a possible relation between mean plasma ET-1 concentration and mean TAV.

The sample size was set at 16 neonates in each group (80% power) to find a difference of one standard deviation in the plasma ET-1 concentration between the groups. Differences were considered significant with a p value of < 0.05.

The study received approval from the Women’s College Hospital Research Ethics Committee and the Hospital for Sick Children Research Ethics Committee.

Results

There were 17 mothers and 18 neonates in each group. In the pre-eclampsia group 16 mothers were treated with antihypertensive drugs, four had abnormal coagulation, and seven had abnormal liver function tests, including two with hypertension, raised liver enzymes and low platelet syndrome. Thirteen mothers in the pre-eclampsia group underwent caesarean section compared with five in the control group; 12 and seven, respectively, had epidural/spinal anaesthesia; two and none, respectively, had general anaesthesia; three and 16, respectively, had spontaneous onset of labour; and eight and none, respectively, were induced. Two fetuses were known to have abnormal umbilical artery blood flow velocity. The characteristics of the groups are shown in table 1. Fifteen neonates in the pre-eclampsia group and 14 neonates in the control group had a patent ductus arteriosus (PDA) detectable by Doppler ultrasonography on day 1; three neonates in each group had a PDA detectable on day 3. Two neonates from each group were treated with indomethacin to close the PDA, but the treatment was carried out after completion of the blood sampling and sonography. Five neonates in the pre-eclampsia group and four from the control group were treated with surfactant for respiratory distress syndrome. There were no statistical differences between the groups at the time of study in respiratory support (ventilator rate, pressures, and inspired oxygen concentration).

Table 1

Characteristics (means and standard deviations) of neonates in pre-eclampsia and control groups

The plasma ET-1 concentrations were significantly higher in the pre-eclampsia group, specifically in maternal venous blood (p=0.012), the umbilical artery (p=0.044) and in day 1 neonatal arterial blood (p=0.027). The results are shown in fig 1.

Figure 1

Mean (SD) plasma ET-1 concentration in control and pre-eclampsia groups. *p<0.05 compared with control group.

Sonographic studies were discontinued before completion in a few neonates either because they were disturbed or because it was impossible to visualise adequately the RA or SMA due to breathing movements or intestinal gas shadows. Doppler studies of the MCA were completed in 16 neonates from each group, while RA and SMA were completed in matched groups of, respectively, 12 and 9 neonates. The differences in blood flow velocity measurements in the MCA, SMA, and RA between both groups are shown in table 2. The MCA PS was significantly higher in the pre-eclampsia group compared with the control group. The TAV, PS, and MV were significantly lower in the pre-eclampsia group compared with the control group. There were no differences between the groups in RA blood flow velocity measurements.

Table 2

Middle cerebral artery, superior mesenteric artery, and renal artery blood flow velocity (mean and SD) (cm/s) in pre-eclampsia and control groups

Subsequent analysis showed that mean SMA TAV was inversely related to mean plasma ET-1 concentration (means of complete data from day 1 and day 3 from 17 infants) (fig 2).

Figure 2

Correlation between mean plasma ET-1 concentration and mean superior mesenteric artery (SMA) time averaged velocity (TAV) in 17 neonates. Means represent data from days 1 and 3 of life; one neonate did not have all measurements on both days.

Discussion

This prospective cohort study has shown that preterm neonates of mothers with pre-eclampsia had fetal hypoxia, increased circulating ET-1, reduced SMA blood flow velocity and an inverse correlation between ET-1 and SMA blood flow velocity. ET-1 acts primarily in blood vessels and only under certain conditions does the compound appear in the circulation. ET-1 concentrations in arterial blood reflect primarily production by the arterial wall. The relation between blood and vascular wall concentrations is not known. Descriptive studies of plasma concentrations in human neonates have not shown an association with gestational age nor with birthweight.24 25 In experimental studies the observed response to ET-1 seems to depend on the vascular bed and the experimental conditions.8 26-30Mothers with pre-eclampsia have higher circulating ET-1 than mothers of a similar gestational age who present with preterm labour.31-35 Both low and high oxygen and shear stress may stimulate ET-1 synthesis.3 7 8 We found relative fetal hypoxia in the pre-eclampsia group, which may have stimulated the higher ET-1 concentrations observed in the fetuses and neonates. Although high plasma ET-1 concentrations have been described in sick neonates,15 25 there were no differences between the groups in the current study with regard to severity of respiratory disease, blood pressure, or incidence of PDA, to account for the high ET-1 concentrations in the pre-eclampsia group.

Blood flow velocity measurements correlated well with actual blood flow, the best measurement being the TAV.36 37 We have shown that neonatal SMA blood flow velocity is reduced in a group of neonates with antenatal hypoxia. The PS, MV, and TAV were all reduced in the SMA of the pre-eclampsia group and therefore these neonates are likely to have reduced intestinal blood flow after birth. We reported measurements of blood flow velocities, as they are more reliable than the resistive or pulsatility indices.22 Studies of neonates with risk factors for necrotising enterocolitis have also shown lower SMA PS38 and MV.39 The reductions in SMA TAV, PS, and MV in the pre-eclampsia group were unlikely to be due to an increased incidence of PDA. PDA reduces SMA ED,40 41 but in our study ED was the same in both groups. Gestational age, birthweight, and enteral feeding are factors that may influence SMA blood flow velocity.42-44 Blood pressure45 and acid base status37 can condition blood flow velocity in cerebral arteries. The impact of these variables was minimised in our study as there were no differences in birthweight and gestational age between the groups and the studies were performed at a time when the neonates were stable. Based on these considerations, we propose that blood borne ET-1 may act as a vasoconstrictor in the SMA, thus explaining the inverse correlation between plasma concentrations of the peptide and SMA TAV. Alternatively, or additionally, changes in shear stress (blood flow velocity) may upregulate the ET-1 system in endothelial cells.46 The latter explanation better explains the persisting increase in ET-1 postnatally.

MCA PS was increased in the pre-eclampsia group. Increased cerebral blood flow has been shown in human neonates after fetal hypoxia.47 Conversely, we did not find any effect of pre-eclampsia on neonatal RA blood flow velocity despite a recent report pointing to a reduction in RA PS after fetal hypoxia.48 Why, then, is SMA selectively susceptible to the constrictor effect of ET-1? There are two possibilities that are not mutually exclusive: a greater influence of ETA over ETB receptors in that vessel or an inadequacy of local relaxing mechanisms.

In conclusion, we have shown that neonates of mothers with pre-eclampsia have increased circulating ET-1 and reduced SMA blood flow velocity, possibly due to fetal hypoxia. In preterm neonates SMA TAV, and hence, actual blood flow, is related to circulating ET-1 concentration after birth. The possibility of a causal link between ET-1 and necrotising enterocolitis raises the prospect of using an ET-1 antagonist, specifically an ETA antagonist, in the prevention and management of this disease. Further investigation is needed to confirm this particular pathophysiological role for ET-1.

Acknowledgments

We thank Mary Lou Ryan and Lois Kelsey for their excellent technical help in performing this study.

This project was made possible by support from the Garfield-Weston Foundation, the Advanced Technology Laboratories (ATL), and the Heart and Stroke Foundation of Ontario, Grant No T-3369.

References

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.